Auris Medical to Announce Business Update and Host Conference Call and Webcast Tomorrow, February 3, 2017

ZUG, Switzerland, Feb. 2, 2017 -- Auris Medical Holding AG (NASDAQ:EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that it will provide a business update tomorrow, Friday, Feb. 3, 2017. Following the announcement, Auris Medical's management team will host a live conference call and webcast at 8:00 am Eastern Time (2:00 pm Central European Time) to discuss the update.

To participate in this conference call, dial 1-877-280-3488 (USA) or +1-646-254-3374 (International), and enter passcode 5782790. A live webcast of the conference call can be accessed on the Investor Relations section of the Auris Medical website at www.aurismedical.com. A replay will be available approximately two hours following the live call.

About Auris Medical

Auris Medical is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology. The Company is focused on the Phase 3 development of treatments for acute inner ear hearing loss (AM-111) and for acute inner ear tinnitus (Keyzilen®; AM-101) by way of intratympanic administration with biocompatible gel formulations. In addition, Auris Medical is pursuing early-stage research and development projects. The Company was founded in 2003 and is headquartered in Zug, Switzerland. The shares of Auris Medical Holding AG trade on the NASDAQ Global Market under the symbol "EARS."

Company contact: Cindy McGee, Head of Investor Relations and Corporate Communications, +41 61 201 13 50, [email protected]

Media contact: David Schull, Russo Partners, 1-858-717-2310, [email protected]